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ABSTRACT: Tumor hypoxia plays a major role in radio- and
chemotherapy resistance in solid tumors. Carbonic Anhydrase
IX (CAIX) is an endogenous hypoxia-related protein, which is
associated with poor patient outcome. The quantitative
assessment of CAIX expression of tumors may steer cancer
treatment by predicting therapy response or patient selection
for antihypoxia or CAIX-targeted treatment. Recently, the
single-photon emission computerized tomography (SPECT)
tracer [111In]In-DTPA-girentuximab-F(ab′)2 was developed
and validated for targeting CAIX. The aim of this study was to
optimize quantitative microSPECT/CT of CAIX expression in vivo in head and neck tumor models. Athymic mice with
subcutaneous SCCNij153 and SCCNij202 head and neck squamous cell carcinoma xenografts were injected with [111In]In-
DTPA-girentuximab-F(ab′)2. First, the protein dose, timing, and image acquisition settings were optimized. Tracer uptake was
determined by quantitative SPECT, ex vivo radioactivity counting, and by autoradiography of tumor sections. The same tumor
sections were immunohistochemically stained for CAIX expression and hypoxia. Highest tumor-normal-tissue contrast was
obtained at 24 h after injection of the tracer. A protein dose of 10 μg resulted in the highest tumor-to-muscle ratio at 24 h p.i. Ex
vivo biodistribution studies showed a tumor uptake of 3.0 ± 0.6%ID/g and a tumor-to-muscle ratio of 8.7 ± 1.4 (SCCNij153).
Quantitative analysis of the SPECT images enabled us to distinguish CAIX antigen blocked from nonblocked tumors, fractions
positive for CAIX expression: 0.22 ± 0.02 versus 0.08 ± 0.01 (p < 0.01). Immunohistochemical, autoradiographic, and
microSPECT/CT analyses showed a distinct intratumoral spatial correlation between localization of the radiotracer and CAIX
expression. Here, we demonstrate that [111In]In-DTPA-girentuximab-F(ab′)2 specifically targets CAIX-expressing cells in head
and neck cancer xenografts. SPECT imaging with indium-labeled girentuximab-F(ab′)2 allows quantitative assessment of the
fraction of CAIX positive tissue in head and neck cancer xenografts. These results indicate that [111In]In-DTPA-girentuximab-
F(ab′)2 is a promising tracer to image hypoxia-related CAIX expression.
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■ INTRODUCTION
Hypoxia is a common feature of solid tumors and has been
associated with increased metastatic behavior, resistance to
chemotherapy and radiotherapy, and a poor patient out-
come.1,2 Carbonic anhydrase IX (CAIX) is a well-known
hypoxia related biomarker. It is a transmembrane protein
expressed on cells that have adapted to hypoxic conditions and
its expression is strongly associated with treatment resistance.3
CAIX is also a potential target for cancer treatment.4,5 A
quantitative method to image CAIX expression could have
prognostic and predictive value and may steer treatment
decisions in cancer patients.
Hypoxic tumor areas are found dispersed throughout the
tumor. Below an oxygen pressure of 20 mmHg, hypoxia
inducible factor (HIF-1α) is stabilized and catalyzes multiple
hypoxia-adaptation pathways including upregulation of CAIX
expression.6,7 The primary function of CAIX is to maintain a
stable intracellular pH by excreting hydrogen ions. Recent
studies also suggested a function in the efflux of lactate8 and in
tumor migration and invasion.9
Many solid tumors express CAIX in hypoxic regions,
including head and neck squamous cell carcinomas
(HNSCC). A meta-analyses by Van Kuijk et al. showed that
CAIX expression was associated with poor outcome in patients
with various tumor types.10 The expression of CAIX in normal
tissue is very low, only the gallbladder and gut express CAIX.5
CAIX expression occurs heterogeneously throughout the
tumor and expression patterns change over time.11 Detection
of CAIX on biopsies does not provide the clinician with an
overview of the total CAIX expression, nor will it be adequate
for tracking CAIX over time.
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CAIX imaging can be used as a prognostic tool since CAIX
has been validated as a prognostic biomarker in solid tumors,
but even more interesting is the potential application in a
predictive setting. Imaging of CAIX could be used for patient
selection for multiple treatments. For example, radiotherapy
tumor dose could be escalated in hypoxic tumor areas to
overcome hypoxia mediated radioresistance.12 Furthermore,
imaging could allow patient selection for antihypoxic or CAIX-
targeting drugs.13
The chimeric antibody girentuximab (cG250) targets the
extracellular domain of humane CAIX, and when labeled with
a fluorophore or radionuclide, it can be used for molecular
imaging of CAIX-positive tumors.14−16 Because girentuximab
is an intact IgG, blood clearance is relatively slow. This slow
clearance hampers imaging at early time points after injection.
To address this issue, we developed a tracer based on
girentuximab-F(ab′)2 fragments.17,18
The aim of this study was to develop a noninvasive imaging
technique to measure CAIX-expression in two different
HNSCC xenografts using the CAIX-targeting compound
[111In]In-DTPA-girentuximab-F(ab′)2 and to correlate the
intratumoral distribution of this radiotracer to the expression
of CAIX and hypoxic tumor areas visualized using
Pimonidazole.
■ EXPERIMENTAL SECTION
Conjugation, Radiolabeling, and Quality Control.
Fifteen milligrams of girentuximab (5 mg/mL chimeric anti-
CAIX antibody G250, Wilex AG) was enzymatically digested
with 250 μg of pepsine (Boehringer, Ingelheim, Germany), in
0.1 M citrate buffer, pH 3.8. After 4 h, digestion was stopped
by adjusting the pH to 7.4 with 0.7 mL of 1 M Tris, pH 10.
The reaction mixture was purified on a HiTrap protein A
column (Sigma-Aldrich Chemie NV, Zwijndrecht, The
Netherlands) in binding buffer, 3 M NaCl/1.5 M glycine
buffer, pH 8.9, to remove the nondigested IgG. Next, the
reaction mixture was concentrated and pepsine was removed
by ultrafiltration in a Centriprep concentrator (MW cutoff 50
kDa). Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) analysis of the purified sample showed
no apparent residual IgG or presence of Fab′ fragments.
Girentuximab and girentuximab F(ab′)2 fragments were
conjugated in a molar ratio of 1:10 at pH 9.5 with
isothiocyanatobenzyl-diethylenetriaminepentaacetic acid
(ITC-DTPA, Macrocyclis, Houston, TX, USA) as described
previously.19 DTPA-conjugated girentuximab and girentux-
imab-F(ab′)2 fragments were radiolabeled with 111InCl
(Mallinckrodt, Petten, The Netherlands), and twice the
volume of 0.5 M 2-(N-morpholino)ethanesulfonic acid
(MES) buffer, pH 5.4, was added. The reaction mix was
incubated at room temperature for 30 min. Labeling efficiency
was between 45 and 84%, with a molar activity of 0.15 MBq/
μmol. Tracers were purified on a PD10 column that was eluted
with PBS 0.5% bovine serum albumin (BSA). Radiochemical
purity was determined by instant thin-layer chromatography
(ITLC) on silica gel chromatography strips (Biodex, Shirley,
NY, USA), using 0.1 M citrate buffer pH 6.0 as the mobile
phase. In case of labeling efficiency < 95%, the labeled product
was purified on a PD-10 column (GE, Woerden, The
Netherlands) that was eluted with 25 mM phosphate-buffered
saline containing 0.5% bovine serum albumin (PBS-BSA).
Radiochemical purity of 111In-labeled girentuximab-F(ab′)2
exceeded 95% in all experiments.
Tumor Models. The Radboud University Medical Center
maintains several patient-derived HNSCC xenograft models,
including SCCNij153 and SCCNij202. These two tumor
models are previously characterized and differ in tumor
biology,18,20,21 but both showed consequent high levels of
CAIX expression in previous experiments.16,20 Phenotype and
morphology of the tumor are regularly assessed by HE and
IHC staining (Pimonidazole, CD31 and Ki67). Six- to 8-week-
old athymic BALB/c nu/nu mice were implanted subcuta-
neously with small tumor pieces (2 mm3) subcutaneously on
the right hind leg (Janvier Laboratories, Le Genest-Saint-Ile,
France). Both sexes were used with regard to translatability
and for ethical reasons. At the start of the experiment, mean
diameter of tumors was 8 mm (range, 6−9 mm, 4−5 weeks
after inoculation). Animals were housed in filter-topped cages
in a specific pathogen-free unit in accordance with institutional
guidelines. Group allocation was randomized and stratified by
tumor size. The Nijmegen Medical Center animal ethics
committee (RUDEC) and the Dutch animal ethics committee
(CCD) approved the project (2016−053). All procedures
were performed according to the Institute of Laboratory
Animal Research guidelines.
Dose-Escalation and Pharmacokinetics of 111In-
girentuximab-F(ab′)2. The optimal dose of girentuximab-
F(ab′)2 to visualize CAIX expression was determined in a
dose−escalation study. Five groups of five mice with
subcutaneous SCCNij153 tumors were injected intravenously
with [111In]In-DTPA-girentuximab-F(ab′)2 at increasing pro-
tein doses of 1, 3, 10, 30, and 100 μg of girentuximab-F(ab′)2
(0.8−2.5 MBq). To demonstrate the specificity for CAIX, a
separate group was preinjected with a blocking dose of 300 μg
unlabeled girentuximab IgG to block all CAIX in vivo and
subsequently (72 h later) injected with 10 μg of 111In-
girentuximab-F(ab′)2. Mice were euthanized by cervical
dislocation 24 h after injection of the radiotracer.
To determine the optimal time-point for CAIX imaging, the
biodistribution of 111In-girentuximab-F(ab′)2 (10 μg, 0.8−1.2
MBq) was evaluated at 4, 24, and 48 h after injection (five
mice per group). To demonstrate the specificity for CAIX, a
separate group (n = 3) received a blocking dose of unlabeled
girentuximab as described previously. Two additional mice
were administered 111In-girentuximab-F(ab′)2 (10 μg, 11−13.7
MBq) and underwent microsingle-photon emission compu-
terized tomography (SPECT)/CT imaging (U SPECT-II;
MILabs) at all three time points. Mice were scanned in prone
position under general anesthesia (isoflurane/air) using the 1.0
mm-diameter multipinhole mouse collimator tube. SPECT
scans were acquired for 45 min, 126 bed positions, followed by
180 s CT scans (615 μA, 65 kV). Mice were injected with the
nitro imidazole derivative Pimonidazole 80 mg/kg i.p. (J. A.
Raleigh Department of Radiation Oncology, University of
North Carolina, USA) to mark hypoxia 50 min prior to cervical
dislocation. Scans were reconstructed with MILabs recon-
struction software, using an ordered-expectation maximization
algorithm with a voxel size of 0,375 mm2, three iterations, and
1.0 mm Gaussian filter. From all mice, tumors and tissue
samples (blood, skin, muscle, small intestine, lung, heart,
kidney, and liver) were harvested and weighed. Subsequently,
radioactivity uptake was determined in a γ-counter (2480
Wizard 3″, LKB/Wallace, PerkinElmer, Boston, MA). Radio-
activity concentrations in the tissues were calculated as
percentage of the injected dose per gram of tissue (%ID/g).
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To correct for radioactive decay, injection standards were
counted simultaneously.
Quantitative microSPECT Imaging of HNSCC. Ten
mice with SCCNij202 tumors were injected with 10 μg of
111In-girentuximab-F(ab′)2 (12.9 ± 1.7 MBq). Half of them
were used to assess the specificity for CAIX and received 300
μg of unlabeled girentuximab 72 h prior to the tracer injection.
At 24 h post-injection, two microSPECT/CT scans were
acquired as described previously.18 In addition, an extra
SPECT scan of the tumor region was acquired for 45 min with
12 scan positions. All mice were injected with Pimonidazole as
described previously.18
Uptake of the radiolabel in the tissues was determined ex
vivo in a γ-counter. Scans were reconstructed as described in
the previous paragraph. Volumes of interest (VOIs) were
drawn around the tumor and the contralateral hind leg muscle
(background region) to quantitatively determine the uptake
(%ID/mL). The measured counts were converted to %ID/mL
using standards with known radioactivity concentrations
scanned with the same SPECT settings.
CAIX positive tumor fractions were determined using a fixed
voxel intensity threshold. Areas with voxel intensity above
threshold were considered CAIX-positive. Thresholds were
corrected for variances in injected dose and decay per
individual mouse. Analyses were performed using the Inveon
Research Workplace software (version 3.0; Siemens Preclinical
Solutions).
Immunohistochemistry and Autoradiography. Half of
the tumor was used for biodistribution measurements. The
other half of each tumor was snap frozen directly after excision
and was cut into sections of 5 μm. These were mounted on
poly-L-lysine coated slides and stored at −80 °C. The sections
were fixed with acetone for 10 min at 4 °C. The intratumoral
distribution of the radiolabeled antibody fragment was
determined by autoradiography. Tumor sections were exposed
to a Fujifilm BAS cassette 2025 overnight (Fuji Photo Film).
Phospholuminescence plates were scanned using a Fuji BAS-
1800 II bioimaging analyzer at a pixel size of 25 × 25 μm.
Images were analyzed with Aida Image Analyzer software
(Raytest). Immunohistochemical staining was performed on
the same tumor sections for CAIX, Pimonidazole, and vessels
as described previously.17
Immunohistochemistry Image Acquisition and Anal-
ysis. Tumor sections were analyzed using a digital image
analysis system, as described previously.22 After whole-tissue
sections had been scanned, gray scale images (pixel size, 2.59 ×
2.59 μm) for vessels, CAIX, and Pimonidazole were obtained
and subsequently converted into binary images. Thresholds for
segmentation of the fluorescent signals were interactively set
above the background staining for each individual marker.
Binary images were used to calculate the CAIX-positive
fraction and hypoxic faction relative to the total tumor. Areas
of necrosis, determined using hematoxylin- and eosin-stained
neighboring tumor sections, were excluded from analysis.
Statistics. Statistical analyses were performed using Graph-
Pad Prism (version 6.0e). The unpaired t test and one-way
ANOVA were used to compare groups and multiple groups.
Linear regression analysis was used to assess correlations
between different parameters, and a P value <0.05 was
considered statistically significant. Results are expressed as
mean value ± SD, unless stated otherwise.
■ RESULTS
Antibody Protein Dose- and Time Optimization in
SCCNij153. The dose-escalation study with 111In-girentux-
imab-F(ab′)2 showed highest tumor uptake in mice, which
received doses up to 10 μg (1, 3, 10 μg; 3.0 ± 0.6, 3.7 ± 1.4,
and 3.1 ± 0.6 %ID/g, respectively). When specific binding was
blocked with an excess unlabeled girentuximab IgG to
determine unspecific tracer uptake, tumor uptake decreased
to 1.5 ± 0.1 %ID/g as shown in Figure 1 (p < 0.05).
Biodistribution of the tracer at 4, 24, and 48 h after injection
showed significant increasing tumor-to-blood (t/b) ratios from
4 to 24 h, but no further increase at 48 h: 1.1 ± 0.4, 19 ± 15,
and 24 ± 13 (p < 0.05). Tumor-to-muscle ratios (t/m) were
more stable: 6.2 ± 2.2, 8.7 ± 1.9, and 7.6 ± 4.5. When specific
binding was blocked with an excess unlabeled girentuximab
IgG, t/b ratios dropped to 0.5 ± 0.1, 5.8 ± 1.3, and 8.0 ± 1.0;
t/m ratios decreased to 2.8 ± 0.7, 2.9 ± 0.4, and 3.8 ± 1.8
(Table 1).
Detecting Intratumoral Heterogeneous Expression of
CAIX in HNSCC Xenografts. Qualitative analysis of the
microSPECT/CT images confirmed the results obtained from
the ex vivo biodistribution studies in the SCCNij153 model. At
4 h post-injection, high background signal resulted in relatively
low contrast between tumor and normal tissue, while images
Figure 1. Dose-escalation of 111In-girentuximab-F(ab′)2. Uptake of
111In-girentuximab-F(ab′)2 in subcutaneous SCCNij153 tumors 24 h
after injection. *p < 0.05.
Table 1. Time Optimization Dataa
time
point (h)
tumor tracer uptake
(%ID/g)
tumor-to-
muscle
tumor-to-
blood
nonblocked 4 3.0 ± 1.5 6.2 ± 2.2 1.1 ± 0.4
24 3.0 ± 1.8 8.7 ± 1.9 19 ± 15
48 1.7 ± 0.8 7.6 ± 4.5 24 ± 13
blocked 4 1.5 ± 0.5 2.8 ± 0.7 0.5 ± 0.1
24 1.1 ± 0.3 2.9 ± 0.4 5.8 ± 1.3
48 0.6 ± 0.1 3.8 ± 1.8 8.0 ± 1.0
aTime optimization experiment of 111In-girentuximab-F(ab′)2 per-
formed on mice baring SCCNij153 tumors. Specific binding was
blocked by preinjecting an excess amount of unlabeled girentuximab
IgG.
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acquired at 24 and 48 h showed better tumor-to-background
contrast (Figure 2). The absolute signal from tumor was higher
at 24 h post-injection compared with 48 h post-injection. Next
to tumor uptake, high tracer uptake in kidneys, liver, and
spleen was observed at all time points (Figure 3)
Quantitative microSPECT imaging in SCCNij202 showed
tumor tracer uptake per volume (%ID/mL) derived from the
whole body SPECT imaging was in line with the
biodistribution results (Pearson correlation coefficient 0.78,
Figure 4A). Tumor-to-muscle and tumor-to-liver ratios derived
from quantitative scans were 3.2 ± 0.7 and 0.34 + 0.08. Next to
tracer uptake per volume, we also determined the CAIX-
positive fraction per tumor. CAIX positive fractions of tumors
without blocking were significantly higher than tumors of mice
that received an excess unlabeled antibody: 0.22 ± 0.02 versus
0.08 ± 0.01 (p < 0.01) (Figure 4B). These data demonstrate
the specificity of 111In-girentuximab-F(ab′)2 for CAIX-positive
tumor areas.
Tracer Uptake Shows Spatial Correlation with CAIX
Expression and Pimonidazole Uptake. Nine xenograft
sections were successfully stained for Pimonidazole and CAIX.
The SCCNij202 xenografts showed mean CAIX-positive
fractions of 0.25 ± 0.06 and mean hypoxic fractions of 0.44
± 0.13. Autoradiography of the tumor sections showed a
heterogeneous uptake pattern of 111In-girentuximab-F(ab′)2 in
the nonblocked group (specific uptake), while uptake in the
blocked group was significantly lower and showed a diffuse
pattern (nonspecific uptake) (Figure 5).
Intratumoral distribution pattern of 111In-girentuximab-
F(ab′)2 was similar to the distribution patterns observed for
CAIX expression as determined immunohistochemically.
Figure 6 shows an example where in vivo microSPECT
imaging of 111In-girentuximab-F(ab′)2 shows a similar
distribution pattern as observed with autoradiography and
immunohistochemistry for CAIX.
■ DISCUSSION
In this study, we determined the optimal conditions to
visualize CAIX expression with 111In-girentuximab-F(ab′)2 in
two different HNSCC xenografts models. The protein dose
escalation experiment showed optimal tracer uptake at
antibody doses ≤10 μg/mouse, which is comparable to intact
girentuximab IgG.23 Biodistribution studies showed high
tumor-to-blood ratios as early as 24 h. Also, biodistribution
studies showed high tracer uptake in kidneys, liver, and spleen,
which is nonspecific since girentuximab does not target murine
CAIX.24 Our intended application is to assess the distribution
of hypoxia as a radioresistance feature within the primary
tumor. In this situation, we know the exact localization of the
tumor, and the application of the new tracer is to study the
heterogeneity of tracer uptake within the tumor. Therefore,
nonspecific uptake in liver and kidneys is not an issue for this
application.
Quantitative analysis of the images indicated that a threshold
could be defined to discriminate CAIX-positive from CAIX
negative areas. Furthermore, preinjection of an excess of
unlabeled girentuximab demonstrated that the uptake of 111In-
girentuximab-F(ab′)2 was specific for CAIX. Importantly, the
heterogeneous uptake of 111In-girentuximab-F(ab′)2 within
tumors showed a spatial correlation with the expression of
CAIX and hypoxia measured by pimonidazole staining
indicating the potential applicability for radiation dose painting
studies.
In recent years, a series of CAIX-targeted imaging agents
have been tested, which were elegantly reviewed in the article
of Lau and colleagues recently.25 The excellent tumor uptake
of intact radiolabeled girentuximab (chimeric G250) has not
been surpassed, but due to their high tumor-to-background
ratios, several other radiotracers (i.e., Tc-99-acetazolamide and
Tc-99-ZCAIX:2) also show great promise (Table 2). Fair
comparison of these tracers is challenging due to the
differences in study design, different tumor models, mice,
time points, doses, etc. In general, larger compounds require a
later time point to obtain images with optimal tumor-to-
normal tissue contrast. Particularly, small molecule and
affibody-based tracers reveal high tumor-to-background
contrast already within 4 h post tracer injection. A head to
head comparison of these promising tracers is warranted to
select the most optimal compound for noninvasive imaging of
CAIX expression.
The importance of early imaging is mostly interesting for
clinical applicability and the possibility to rapidly repeat scans
to track change in live uptake induced by treatment. Because of
Figure 2. Serial MicroSPECT images of mice bearing a SCCNij153
xenograft were obtained 4, 24, and 48 h post-injection of 111In-
girentuximab-F(ab′)2. The circles indicate the tumor.
Figure 3. Time optimization biodistribution of 111In-girentuximab-
F(ab′)2 in SSCNij153 tumors and selected normal tissues at 4, 24,
and 48 h post-injection.
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the long half-life of CAIX,26 change in CAIX is slower than
change in pO2. Therefore, when CAIX imaging is used for
therapy monitoring early imaging is possibly less relevant
compared to imaging with a nitroimidazole derivative based
hypoxia radiotracer.
Although CAIX is considered to be an intrinsic hypoxia
related marker in tumors, there are a few limitations with the
use of CAIX imaging that should be taken into account.
Besides hypoxia, there are different mechanisms that are also
involved in upregulation of CAIX. For example, decreasing
extracellular pH precludes CAIX expression.27 Furthermore,
pathways such as PI3K28 or the unfolded protein response29
can also induce CAIX expression. Finally, not all hypoxic
tumors express CAIX.30 Apart from these uncertainties in the
mechanism of upregulation, CAIX expression in solid tumors
clearly has a negative prognostic value and is associated with
poor treatment outcome.10
Immunohistochemical staining of vessels, CAIX, and
hypoxia showed similar patterns as seen before in these
HNSCC xenografts by our group.21,30 Generally, CAIX was
expressed at a shorter distance from the vessels compared to
hypoxia (pimonidazole staining). Also, areas of mismatch were
found, with a positive pimonidazole staining and no CAIX
expression, or vice versa (Supporting Figure S1). This can be
explained by multiple reasons, which are mentioned above.
Another explanation can be found in changes in perfusion
because it takes several hours for cells to adapt to hypoxia and
express CAIX.26
Most CAIX-targeting radiotracers have been studied in renal
cell carcinoma models (i.e., SK-RC-52) in which CAIX is
expressed constitutively at a high level on the tumor cells. The
CAIX antigen is expressed in the SK-RC-52 due to a mutation
in the Von Hippel Lindau (VHL) gene, which leads to
constitutive overexpression of HIF1α, which is not related to
hypoxia. Although this homogeneous high expression allows
determining the specificity of CAIX-targeting of these tracers,
the CAIX expression levels in this model are much higher than
the expression levels found in hypoxic tumors without the
Figure 4. SPECT quantification. (A) Scatterplot correlating tumor SPECT quantification with tumor tracer uptake in the SCCNij202 xenograft.
(B) CAIX positive fraction determined by SPECT quantification. Both groups were injected with 10 μg of 111In-girentuximab-F(ab′)2, and the
blocked group was preinjected with 300 μg of unlabeled girentumab IgG (p < 0.001).
Figure 5. Autoradiography images acquired overnight. Top row shows tumors from blocked group (mice were preinjected with 300 μg of unlabeled
girentuximab IgG); bottom row shows tumors from the nonblocked group.
Figure 6. Visualization of tumor heterogeneity. Example SCCNij202
xenograft imaged after immunohistochemical staining (A,B; green =
pimonidazol, red = CAIX, blue = vessels), autoradiography (C), and
microSPECT (D).
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VHL mutation. Thus, these renal cell carcinoma models are
relevant for targeting, but not to study CAIX in hypoxic tumor
areas. Therefore, we selected HNSCC xenograft models to
characterize 111In-girentuximab-F(ab′)2, and because in
patients with solid tumors, such as HNSCC, hypoxia and
CAIX expression are highly correlated with treatment
resistance.
Our high-resolution SPECT images of two different
HNSCC xenografts, SCCNij202 and SCCNij153, showed
heterogeneous tumor uptake. Autoradiographic and immuno-
histochemical analysis of the same tumor sections showed that
uptake correlated with CAIX expression. Also, positive areas
were mainly located around necrotic areas. Our results
demonstrate that it is feasible to image and quantify the
fraction of hypoxic areas in HNSCC tumors. Although
immunohistochemistry provides information on a micrometer
scale, it generally does not allow measurement of whole tumor
lesions and potentially also its metastases. Thus, noninvasive
imaging provides a better overview of the total hypoxic fraction
of a certain tumor and allows sequential imaging over time of
the same lesion.
In the clinical setting, this overview is important since it
provides important information on the tumor biology. For
example, accurate CAIX imaging could enable intensity
modulated radiotherapy “dose painting” with specific boosting
of CAIX positive, radioresistant tumor regions.31
Girentuximab-F(ab′)2 has been successfully labeled with
zirconium-89, which has a similar half-life as indium; therefore,
PET imaging with this tracer is also feasible.17 Previously, we
showed that In-111-labeled and Zr-89-labeled girentuximab-
F(ab′)2 have a similar biodistribution.18 Preclinically, In-111 is
the preferred isotope with (ultra high resolution) SPECT
scanning, but in clinical studies, Zr-89 is preferable because of
the higher resolution of PET in clinical applications. We think
the selection and optimization of an optimal radiotracer is
crucial.
Even with promising results in rodent studies, translation
and implementation of CAIX imaging to the clinic will be a
challenge. Girentuximab IgG has been tested in several clinical
studies and showed high tumor to background ratios, being
among the highest reported in studies of solid tumors.32
Therefore, we expect it to be an excellent tracer to image CAIX
in head and neck tumors. However, future clinical studies have
to demonstrate that this is indeed the case.
The first step for the clinical development of this tracer
could be a feasibility study (phase I) in patients with head and
neck cancer. In later studies, the correlation between the CAIX
PET signal and radiation sensitivity could be investigated. The
most straightforward clinical application of CAIX imaging is in
the function of treatment prediction. As a stable hypoxia-
related marker, CAIX potentially is a predictive marker for
hypoxia targeting or modulating treatment. At the moment,
several promising CAIX targeting and hypoxia modulating
treatments are studied in clinical trials (NCT03450018,
NCT02020226). If these studies prove to be successful,
accurate pretreatment discrimination between CAIX positive
and negative tumors could help patient selection and thus
improve clinical outcome for patients with solid tumors, such
as head and neck cancer.
■ CONCLUSION
Here, we demonstrate the feasibility to quantify the CAIX-
positive fraction in two different HNSCC xenograft models,
using SPECT and 111In-girentuximab-F(ab′)2. These results
show that 111In-girentuximab-F(ab′)2 is a promising tracer to
image hypoxia-related CAIX expression and may be used in the
future to identify patients with therapy resistant tumors to
individualize cancer treatment.
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